Literature DB >> 6935461

High incidence and characterization of glucocorticoid receptors in human malignant melanoma.

H S Bhakoo, R J Milholland, R Lopez, C Karakousis, F Rosen.   

Abstract

The glucocorticoid receptor was characterized in biopsy samples from patients with recurrent malignant melanoma. Glucocorticoid receptors were measured by the charcoal-adsorption technique. Tumor cytosol from approximately 86% (25/29) of the patients contained large quantities of receptors (20-324 fmol/mg protein). The dissociation constant of this cytoplasmic receptor was determined to be 2-22 nM. This binding component sedimented at 7.1S on sucrose gradients of low ionic strength and dissociated into lower molecular weight components that sedimented at 4.4S on sucrose gradients of high ionic strength. Receptor binding was specific for glucocorticoids. Although progestins competed well for the binding that is typical for glycocorticoid receptor as reported in the literature, other steroids, e.g., 17 beta-estradiol and 5 alpha-dihydrotestosterone, were only weak competitors. These results demonstrated that this neoplasm contains large quantities of glucocorticoid receptors that are similar in their physicochemical characteristics to those found in normal tissues. This finding in human melanoma biopsy specimens may be of therapeutic value in the management of patients with malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6935461

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Detection of glucocorticoid sensitive secretory proteins from human melanoma cells.

Authors:  D M Di Sorbo
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

2.  Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells.

Authors:  Judit Dobos; István Kenessey; József Tímár; Andrea Ladányi
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

Review 3.  Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer.

Authors:  K Karimi; T H Lindgren; C A Koch; Robert T Brodell
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

4.  Loss of glucocorticoid receptors in B16BL6 murine melanoma associated with serial transplantation, metastatic selection and altered growth properties.

Authors:  G P Risely; G V Sherbet
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

5.  The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.

Authors:  P J Selby; J L Millar; T A Phelps; M Y Gordon; R Wilkinson; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Overexpression of glucocorticoid receptor in human pancreatic cancer and in xenografts. An immunohistochemical study.

Authors:  Sándor Békási; Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2009-02-28       Impact factor: 3.201

7.  Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.

Authors:  R Becher; O Kloke; K Höffken; M E Scheulen; U B Wandl; H Bojar; C G Schmidt
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

8.  Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods.

Authors:  Honghao Duan; Ke Jiang; Dengke Wei; Lijun Zhang; Deliang Cheng; Min Lv; Yuben Xu; Aimin He
Journal:  Onco Targets Ther       Date:  2017-12-20       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.